Summary of Stevanato Group Conference Call Company Overview - Stevanato Group has 70 years of operational excellence and is a leading player in the biopharmaceutical and diagnostic industry, providing mission-critical solutions [2][4] - The company operates through two segments: Biopharmaceutical and Diagnostic Solutions (88% of revenue) and Engineering (12% of revenue) [2] Core Business Insights - The company offers a full portfolio of pharmaceutical glass products, including cartridges, vials, and syringes, which are critical for drug delivery [2][3] - High-value products, such as Nexa prefilled syringes, have the highest marginality and are essential for meeting stringent performance requirements [3][5] - Stevanato Group has a strong market position, being a leader in pen cartridges and ready-to-use vials, and second in prefilled syringes [4] Financial Performance - In 2025, the company achieved a 9% growth on a constant currency basis, with high-value solutions growing approximately 30% year-over-year, representing about 46% of total revenue [5][6] - Revenue from GLP-1s accounted for approximately 19%-20% of total revenue, growing over 50% compared to 2024 [5] - The company expanded gross profit margin by 160 basis points and operating profit margin by 220 basis points compared to 2024 [6] - For fiscal year 2026, the company expects top-line growth of 8%-10% on a constant currency basis, with high-value solutions projected to represent 47%-48% of total revenue [6][10] Market Trends and Growth Drivers - The biologics market is identified as a key growth area, with a 40% increase in customers ordering high-value prefilled syringes in non-GLP-1 applications [6][20] - The company anticipates growth in the vial market, particularly in sterile vials, with a projected mid- to high-single-digit growth in 2026 [17] - The biosimilars market is also expected to grow significantly, especially in regions like India and China [20][21] Capacity Expansion and Investment - Stevanato Group is investing heavily in capacity expansion, with a capital expenditure target of around EUR 250 million in 2026, primarily for high-value solutions [35][36] - The company is ramping up production in its new facilities in Fishers and Latina, with a focus on sterile cartridges and Nexa syringes [30][36] - The Fishers plant is expected to be fully operational by 2028, while the Latina plant is ahead in ramp-up compared to Fishers [30] Competitive Positioning - The company believes it has gained share in the biologics market rather than competing directly with other companies [38] - Stevanato Group is focused on high-value products, with gross profit margins typically between 40%-70% [50] Challenges and Risks - The company faces temporary headwinds from unfavorable currency exchange rates and tariffs, which impacted profits in 2025 [6][8] - There is a noted slowdown in decision-making for new projects, which may affect the Engineering segment's performance in 2026 [46] Conclusion - Stevanato Group is well-positioned for future growth, driven by strong demand for high-value solutions and a robust pipeline in biologics and biosimilars, despite facing some market challenges and currency headwinds [7][10][46]

Core Insights - Artisan Small Cap Fund reported strong absolute returns in Q4 2025, outperforming both the Russell 2000® Growth Index and the Russell 2000® Index despite elevated volatility and shifting market sentiment influenced by various political and economic factors [1] Group 1: Fund Performance - The Fund seeks to invest in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1] - In Q4 2025, the market leadership shifted back to companies with durable profit cycles, while the Fund's full-year performance trailed both indexes [1] Group 2: Stevanato Group S.p.A. Analysis - Stevanato Group S.p.A. (NYSE:STVN) is highlighted as a key holding, providing specialty glass and plastic packaging to the healthcare industry [2][3] - As of March 16, 2026, Stevanato Group's stock closed at $15.35 per share, with a one-month return of -3.82% and a 12-month return of 29.46% [2] - The stock faced challenges due to market concerns regarding Eli Lilly's pending launch of an oral GLP-1, impacting Stevanato's profit cycle related to vial and syringe production [3] - Despite the challenges, the company remains a focus for investment due to anticipated growth in liquid-based biological drugs and increased drug volume from Medicare and Medicaid coverage of GLP-1s [3]

Core Insights - Stevanato Group will participate in the KeyBanc Capital Markets Virtual Healthcare Forum on March 17-18, 2026, presenting on March 17 from 9:45 to 10:20 a.m. ET [1] - The company is a leading global provider of drug containment, drug delivery, and diagnostic solutions, serving the pharmaceutical, biotechnology, and life sciences industries [1] - Stevanato Group reported a 7% revenue growth for fiscal year 2025, with a 9% increase on a constant currency basis, driven by record revenue from high-value solutions and expanded margins [1] Financial Performance - For Q4 2025, revenue increased by 5% (7% on a constant currency basis) to €346.5 million [1] - In Q3 2025, revenue rose by 9% (11% on a constant currency basis) to €303.2 million, with high-value solutions accounting for a record 49% of total revenue [1]

Group 1 - The company is responsible for the development of transcript-related projects and publishes thousands of quarterly earnings calls each quarter [1] - The coverage of transcript-related content is continuing to grow and expand [1] - The purpose of the profile is to share new developments related to transcripts with readers [1]

Core Viewpoint - Stevanato Group (STVN) reported its Q4 and Fiscal Year 2025 results, with the stock experiencing a decline of approximately 22.39% following a 10% increase on the reporting day, March 04, 2026 [1] Financial Performance - The company has shown a significant stock price fluctuation, indicating potential volatility in investor sentiment [1] Investment Sentiment - Despite the recent stock decline, there is a reiteration of a "Buy" recommendation from hedge professionals focusing on fundamental, income-oriented, long-term analysis across sectors globally in developed markets [1]

Company Overview - Stevanato Group S.p.A. is a leading entity in the pharmaceutical and healthcare industry, known for its production of glass containers and integrated systems for drug delivery, with a strong global presence and innovative solutions [1] Financial Performance - The recent Q4 2025 earnings call provided insights into Stevanato Group's financial performance, discussing revenue, profit margins, and future outlook, which are crucial for understanding the company's operational strategies and market conditions [3] - Stevanato Group's market capitalization stands at approximately $4.37 billion, with a trading volume of 388,631 shares, indicating significant stock volatility over the past year [4][5] Stock Performance - Paul Knight from KeyBanc set a price target of $32 for STVN, suggesting a potential price increase of approximately 99.88%, while the stock is currently priced at $15.99, reflecting a decrease of 8.63% today [2][5] - Over the past year, the stock has reached a high of $28 and a low of $13.91, indicating the potential for significant price movements [4]

Core Viewpoint - Stevanato Group S.p.A. is a prominent player in the pharmaceutical and healthcare sector, recognized for its glass containers and drug delivery systems, and competes with companies like Gerresheimer and Schott AG [1] Financial Performance - In Q4 2025 earnings call, the company reported a current stock price of $15.94, reflecting an 8.91% decrease and a change of $1.56 from its previous value, likely influenced by market reactions to the earnings announcement [3] - The stock has shown volatility, with a trading range between $15.88 and $16.99 on the day, and over the past year, it reached a peak price of $28 and a low of $13.91, indicating significant price fluctuations [4] Market Position - The company's market capitalization is approximately $4.35 billion, highlighting its substantial presence in the industry [4] - A trading volume of 231,436 shares on the NYSE indicates strong investor interest and engagement with the company's recent developments [5] Analyst Ratings - KeyBanc upgraded its rating for STVN to "Overweight" on March 5, 2026, with the stock valued at $16.58, reflecting confidence in the company's potential to outperform the market, although the recommendation to "hold" suggests maintaining existing positions without new investments [2]

Management View - Stevanato Group reported a 9% increase in total company revenue at constant-currency rates and a 7% increase on a reported basis for fiscal 2025 compared to 2024 [2] - The company highlighted double-digit top-line growth in the Biopharmaceutical sector [2] Future Outlook - Stevanato Group has set a revenue target of up to €1.308 billion for 2026, with high-value solutions expected to account for 48% of sales [2]

Risk Management - The company faces significant risks related to product quality, which could lead to lost sales, increased costs, and damage to reputation if products do not meet quality standards [52]. - The company is exposed to international market risks, including geopolitical tensions, which could materially affect its liquidity and financial condition [52]. - The company’s operations are subject to various regulatory requirements, and failure to comply could adversely affect its business and share price [60]. - The company is subject to complex tax laws and potential audits across multiple jurisdictions, which could increase tax liabilities and affect financial results [85][87]. - The company is subject to various laws and regulations, and any changes could significantly impact its ability to market and sell products, especially in the healthcare sector [132][135]. - Noncompliance with applicable laws and regulations could lead to significant sanctions, including product recalls and operational restrictions, adversely affecting the company's reputation and financial condition [136]. - The company is subject to financial and economic sanctions that may restrict business operations in certain jurisdictions, particularly in relation to Russia and Ukraine [146]. - The company must comply with U.S. and EU anti-corruption laws, which could expose it to civil and criminal penalties [144]. Market Dynamics - The company must continuously develop and acquire new products and services to remain competitive in a rapidly changing technological landscape [62]. - The company may face significant competition in implementing revenue growth strategies, which could impact its market position [52]. - The company faces significant competition across all business segments, with 53.6% of revenues derived from the top ten customers, and one customer representing 12.0% of revenues in 2025 [95]. - The company is focused on managing growth and expanding its operations while addressing the complexities and risks associated with new facilities and acquisitions [100][105]. Financial Performance - The backlog may not accurately predict future revenue, and the company might not realize anticipated revenue reflected in the backlog [66]. - The company's backlog as of December 31, 2025, was approximately €871 million, an increase from €853 million at the end of 2024, indicating a growth of about 2.1% year-over-year [68]. - The backlog does not necessarily correlate with future direct revenue due to factors such as project cancellations, delays, and customer ordering patterns, which can lead to fluctuations [68]. - The company’s financial condition may be affected by fluctuations in currency exchange rates and interest rates due to its multinational operations [52]. - The average days sales outstanding for 2025 decreased to approximately 61 days, down from approximately 75 days for 2024 [150]. - A significant majority of outstanding trade receivables are not covered by collateral or credit insurance, increasing credit risk exposure [150]. Operational Challenges - The company is highly dependent on maintaining relationships with suppliers and service providers, which is crucial for its financial condition and results of operations [52]. - Relationships with suppliers are critical, and any loss of key suppliers or unfavorable contract terms could materially affect the company's financial condition and results [74][75]. - The ongoing conflict between Russia and Ukraine has caused significant fluctuations in energy prices, which may impact the company's ability to source materials at reasonable terms [76]. - The company faces risks related to the availability and quality of materials, which could disrupt production and adversely affect operating results [78]. - Manufacturing facilities are subject to operational hazards that could lead to production interruptions, impacting financial performance [83]. - The company is vulnerable to risks from third-party vendors experiencing cyber-attacks, which could compromise its networks and data integrity [176]. Innovation and Development - The company’s ability to innovate and invest in new products is critical, as failure to do so may result in decreased market desirability of its offerings [63]. - The company is selectively pursuing acquisitions and technology collaborations to augment its product and service portfolio, having completed several acquisitions in recent years [107]. - The company acquired Perugini S.r.l. on November 8, 2023, to enhance integration of critical technologies into its production process [104]. - The company maintains close relationships with customers during product development, which is crucial for retaining business and integrating new products into its portfolio [96][106]. Compliance and Legal Risks - The company is subject to complex and evolving indirect tax obligations, which may lead to adjustments by tax authorities [160]. - The company may face unexpected liabilities from acquisition agreements due to limited indemnification provisions [165]. - The company may be subject to litigation regarding intellectual property rights, which could impact its ability to market products and technologies [216]. - The company may incur substantial expenses and damages if found infringing third-party patent rights, potentially delaying or terminating product development and sales activities [217]. Environmental and Regulatory Factors - The uncertain effects of climate change and potential legislation could lead to increased costs and business interruptions, affecting operational and financial decisions [196]. - New regulations, such as the European Sustainability Reporting Standards (ESRS) and California's Climate Corporate Data Accountability Act, may impose additional compliance costs [197]. - The introduction of stringent data protection regulations in China may increase compliance costs and impact the company's operations and data transfer practices [127]. Intellectual Property - The company relies on trade secrets and confidential know-how for technology protection, which are difficult to safeguard against misappropriation [200]. - Patent protection is critical for the company's competitive position, but the patent prosecution process is complex and costly, potentially limiting the ability to secure necessary patents [203][204]. - The company may face challenges in maintaining licenses for proprietary technology, which could hinder product development and commercialization [210]. - Third-party claims of patent infringement could result in substantial costs and delays in product development and commercialization [214]. Human Resources - The company is highly dependent on its management and skilled employees, with intense competition for talent potentially impacting its growth and operational success [73]. - The company employs approximately 6,010 employees as of December 31, 2025, with 58% based in Italy [156]. Shareholder and Market Perception - The dual class structure of shares may lead to volatility in market price and affect investor perception, as Stevanato Holding S.r.l. holds 93.09% of voting rights [241]. - The trading market for the company's shares may decline if analysts publish unfavorable research or cease coverage [240].

Revenue Growth - Total Company revenue increased by 9% at constant currency and 7% on a reported basis for FY 2025, driven by strong growth in the Biopharmaceutical and Diagnostic Solutions Segment [15]. - High-Value Solutions (HVS) revenue grew by 29% year-over-year in 2025, contributing significantly to margin expansion [15]. - Revenue from GLP1s accounted for approximately 19% to 20% of total Company revenue, growing over 50% compared to 2024 [21]. - Q4 2025 revenue reached €346 million, a 31% increase year-over-year, with HVS representing 49% of total revenue [37]. - The Company expects continued growth in the GLP market, driven by various factors including biosimilar launches and next-gen incretins [21]. - FY 2026 revenue guidance is set between €1.260 billion and €1.290 billion, implying a growth rate of 6% to 9% [46]. - The company plans to achieve a reported revenue of €1,290.0 million for 2026, with an adjusted EBITDA guidance of €331.8 million [79]. Profitability and Margins - Adjusted EBITDA increased by 7% to €97.7 million, with an adjusted EBITDA margin of 28.2% [38]. - Adjusted EBITDA for FY 2025 was €287.4 million, representing an 18.8% increase compared to the previous year [64]. - The adjusted operating profit margin for FY 2025 was 17.7%, up from 16.2% in FY 2024, reflecting improved operational efficiency [65]. - Gross profit margin for the BDS Segment improved to 31.6%, driven by a favorable mix of HVS and operational improvements [41]. Capital Expenditures and Cash Flow - Free cash flow for fiscal year 2025 was €18.4 million, with cash from operating activities at €286.1 million, exceeding expectations due to better performances in TWC and timing of capital expenditures [45]. - Total capital expenditures for FY 2026 are projected to be between €270 million and €290 million, with net customer contributions reducing capex to between €240 million and €260 million [49]. - The addition to property, plant, and equipment for the year ended December 31, 2025, was €283.6 million, reflecting an increase of €8.0 million from the previous year [74]. - The company recorded cash flow from operating activities of €286.1 million for the year ended December 31, 2025, compared to €155.8 million for the previous year [78]. Customer Demand and Market Trends - In 2025, the number of customers ordering High-Value PFS increased by 40%, indicating strong market demand [21]. - HVS revenue reached a record level of €171.4 million, accounting for 56% of segment revenue, with a year-over-year growth of 31% driven by strong demand for high-value Nexa® syringes [44]. - The company has over 9,000 injectable drug products in the global pipeline, with more than 60% being biologics, indicating strong future growth potential [55]. Segment Performance - The Engineering Segment experienced a revenue decline, with Q4 2025 revenue at €39 million, down from €51 million in Q4 2024 [42]. - Revenue decreased by 23% year-over-year to €39.4 million, primarily due to lower sales from glass converting and assembly lines, partially offset by growth in pharma visual inspection [43]. Financial Position - As of December 31, 2025, the net debt was €337.7 million, slightly higher than €335.0 million as of December 31, 2024 [76]. - Capital employed as of December 31, 2025, was €1,824.2 million, an increase from €1,739.4 million as of December 31, 2024 [72]. Tax and Start-up Costs - The tax rate for FY 2026 is expected to be approximately 26.8% [49]. - Start-up costs for new plants in Fishers, Indiana, and Latina, Italy, amounted to €3.8 million for Q4 2024 and €13.0 million for the full year 2024 [69]. - Restructuring and related charges for the year ended December 31, 2024, totaled €4.0 million, primarily related to employee costs [70].